articleNature MedicineAug 27, 2023HYBRID OA

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

BABarry A. BorlaugDWDalane W. KitzmanMJMelanie J. DaviesSRSøren RasmussenEBEric Barros

Mayo Clinic in Arizona · Wake Forest University · +29 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Abstract In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This prespecified analysis examined the effects of semaglutide on dual primary endpoints (change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and body weight) and confirmatory secondary endpoints (change in 6-minute walk distance (6MWD), hierarchical composite (death, HF events, change in KCCQ-CSS and 6MWD) and change in C-reactive protein (CRP)) across obesity classes I–III (body mass index (BMI) 30.0–34.9 kg m − 2 , 35.0–39.9 kg m − 2 and ≥40 kg m − 2 )…

Citation impact

185
total citations
FWCI
39.22
Percentile
100%
References
16
Citations per year

Authors

28

Topics & keywords

Topics
Keywords
  • Medicine
  • Semaglutide
  • Internal medicine
  • Obesity
  • Heart failure with preserved ejection fraction
  • Cardiology
  • Weight loss
  • Blood pressure
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding